Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer
Since the release of the DESTINY-Breast04 (DB-04) trial findings in June 2022, the field of
pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The …
pathology has seen a renaissance of HER2 as a predictive biomarker in breast cancer. The …
Immune biomarkers in triple-negative breast cancer: improving the predictivity of current testing methods
Triple-negative breast cancer (TNBC) poses a significant challenge in terms of prognosis
and disease recurrence. The limited treatment options and the development of resistance to …
and disease recurrence. The limited treatment options and the development of resistance to …
Advances in breast cancer risk modeling: Integrating clinics, imaging, pathology and artificial intelligence for personalized risk assessment
F Pesapane, O Battaglia, G Pellegrino… - Future …, 2023 - Taylor & Francis
Breast cancer risk models represent the likelihood of developing breast cancer based on
risk factors. They enable personalized interventions to improve screening programs …
risk factors. They enable personalized interventions to improve screening programs …
Epigenetic regulation of HOXA2 expression affects tumor progression and predicts breast cancer patient survival
FDE De Palma, JG Pol, V Carbonnier… - Cell Death & …, 2025 - nature.com
Accumulating evidence suggests that genetic and epigenetic biomarkers hold potential for
enhancing the early detection and monitoring of breast cancer (BC). Epigenetic alterations …
enhancing the early detection and monitoring of breast cancer (BC). Epigenetic alterations …
Automated quantification of HER2 amplification levels using deep learning
CW Wang, KL Chu, TS Su, KW Liu… - IEEE Journal of …, 2024 - ieeexplore.ieee.org
HER2 assessment is necessary for patient selection in anti-HER2 targeted treatment.
However, manual assessment of HER2 amplification is time-costly, labor-intensive, highly …
However, manual assessment of HER2 amplification is time-costly, labor-intensive, highly …
Characterization of KIF20B as a novel prognostic biomarker and therapeutic target for breast cancer
RW Mbugua, A Takano… - International …, 2024 - spandidos-publications.com
Despite advances in treatment and early detection, breast cancer remains one of the most
common types of cancer and is the second leading cause of cancer death after lung cancer …
common types of cancer and is the second leading cause of cancer death after lung cancer …
Toxicological profiling of a de novo synthesized benzimidazole derivative with potent and selective proapoptotic potentials against breast cancer
EK Farrag, WM Aziz, SE Shaker, H Shawky… - Food and Chemical …, 2023 - Elsevier
This study aimed to investigate the toxicological profile of 1-(6-(1H-benzo [d] imidazole-2-yl)-
2-methylpyridin-3-yl) ethanone (BMPE), both in vitro and in vivo. The proapoptotic/necrotic …
2-methylpyridin-3-yl) ethanone (BMPE), both in vitro and in vivo. The proapoptotic/necrotic …
[HTML][HTML] Prognostic value of cyclin B1 and cyclin B2 expression in breast cancer: A systematic review and updated meta-analysis
J Kang, H Jung, H Kim - Medicine, 2024 - journals.lww.com
Background: Cyclin B1 and cyclin B2 are key regulators of cell cycle progression and have
been implicated in the prognostic significance of various cancers. This meta-analysis aimed …
been implicated in the prognostic significance of various cancers. This meta-analysis aimed …
UTILIZAÇÃO E GESTÃO DO TRASTUZUMAB DERUXTECANO NA PESSOA COM CANCRO DE MAMA: RECOMENDAÇÕES.
AP Amorim, AR Chemela, R Cordeiro, J Freitas… - Onco …, 2024 - search.ebscohost.com
É essencial sensibilizar os doentes para que reportem quaisquer sinais e sintomas durante
o tratamento com trastuzumab deruxtecano. A atuação imediata com as recomendações …
o tratamento com trastuzumab deruxtecano. A atuação imediata com as recomendações …